Last reviewed · How we verify
COR-001
At a glance
| Generic name | COR-001 |
|---|---|
| Sponsor | University of Colorado, Denver |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Hyperparathyroidism
- Pain in extremity
- Cellulitis
- Cough
- Decreased appetite
- Diabetic foot
- Dyspnoea
- Foot deformity
- Hypertensive emergency
- Hypoaesthesia oral
- Intraocular lens implant
- Iris neovascularisation
Key clinical trials
- Trial to Evaluate Reduction in Inflammation in Patients With Advanced Chronic Renal Disease Utilizing Antibody Mediated IL-6 Inhibition (PHASE2)
- Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of COR-001 (PHASE1, PHASE2)
- A Study of Patients With Chronic Kidney Disease to Assess the Safety of a Single Dose of COR-001 (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- COR-001 CI brief — competitive landscape report
- COR-001 updates RSS · CI watch RSS
- University of Colorado, Denver portfolio CI